Shanghai Abelzeta Ltd.

This early-phase study tests a new treatment called C-CAR031 for people with advanced squamous cell lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target a protein called GPC3 found on cancer cells. …

This study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to target two markers on cancer cells (CD19 and CD20). The goal is…

This early-phase trial tests a new treatment called A-CAR032 for men with a tough-to-treat type of advanced prostate cancer that has stopped responding to standard hormone therapy. The study aims to see if the treatment is safe and to get an early look at whether it can shrink tu…

This study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is t…